Aceso Life Science Group Limited
SEHK:474 Rapporto sulle azioni
Cap. di mercato: HK$428.1m
Aceso Life Science Group Gestione
Gestione criteri di controllo 2/4 Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave Percentuale dello stipendio del CEO n/a Mandato del CEO no data Proprietà del CEO n/a Durata media del management 8yrs Durata media del Consiglio di amministrazione 12.3yrs
Aggiornamenti recenti sulla gestione
Insufficient new directors Aug 01
Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024 Jul 26
Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director Feb 23
Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023 Jul 29
Aceso Life Science Group Limited Announces Change of Company Secretary Aug 27
Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022 Jul 29
Mostra tutti gli aggiornamenti
New minor risk - Share price stability Aug 19
Insufficient new directors Aug 01
Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023) Jul 30
Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024 Jul 26
New minor risk - Market cap size Jul 24
New major risk - Revenue and earnings growth Jun 28
Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024 Jun 15
Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director Feb 23
First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023) Nov 30
New major risk - Revenue size Nov 30
Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023 Nov 21
Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023 Nov 17
Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022) Aug 01
Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023 Jul 29
Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022) Jun 29
Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023 Jun 16
New minor risk - Market cap size Jun 14
First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022) Dec 30
First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022) Nov 30
Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022 Nov 22
Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022 Nov 18
Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million. Oct 29
Aceso Life Science Group Limited Announces Change of Company Secretary Aug 27
Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021) Aug 03
Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022 Jul 29
Full year 2022 earnings released Jul 01
Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022 Jun 18
Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022 Jun 11
Senior Consultant recently bought HK$18m worth of stock Apr 27
Senior Consultant recently bought HK$4.6m worth of stock Mar 08
First half 2022 earnings: Revenues and EPS in line with analyst expectations Nov 29
Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020) Jul 27
Non-Executive Director Yao Li has left the company Jul 13
Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020) Jun 27
Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders? Feb 23
Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently? Jan 01
Senior Consultant recently sold HK$5.0m worth of stock Jan 01
First half 2021 earnings released: HK$0.07 loss per share Dec 19
New 90-day low: HK$0.23 Dec 17
New 90-day low: HK$0.24 Nov 30
First half 2021 earnings released: HK$0.07 loss per share Nov 28
Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020 Nov 06
New 90-day low: HK$0.28 Oct 13
Senior Consultant recently bought HK$852k worth of stock Oct 09
Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million. Oct 07
Senior Consultant recently bought HK$2.8m worth of stock Sep 30
New 90-day high - HK$0.34 Aug 04
Full year earnings released - HK$0.049 loss per share Aug 03
Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020 Jul 06
AMMINISTRATORE DELEGATO Aceso Life Science Group non ha un CEO, o non abbiamo dati su di loro.
Gruppo dirigente Nome Posizione Mandato Compensazione Proprietà CFO & Executive Director 13.9yrs HK$5.00m 0.82% HK$ 3.5m Senior Consultant 9.2yrs HK$13.20m 57.5% HK$ 246.2m Executive Director no data HK$600.00k 0.0099% HK$ 42.6k Chief Operating Officer 6.2yrs Nessun dato Nessun dato Group Financial Controller 8yrs Nessun dato Nessun dato Company Secretary 2.3yrs Nessun dato Nessun dato
Mostra di più
Gestione esperta: Il team dirigenziale di 474 è esperto e expertise (durata media dell'incarico 8 anni).
Membri del Consiglio di amministrazione Nome Posizione Mandato Compensazione Proprietà CFO & Executive Director 11.2yrs HK$5.00m 0.82% HK$ 3.5m Executive Director 12.4yrs HK$600.00k 0.0099% HK$ 42.6k Independent Non-Executive Director 12.3yrs HK$200.00k 0.0099% HK$ 42.6k Independent Non-Executive Director 12.7yrs HK$200.00k 0.0099% HK$ 42.6k Independent Non-Executive Director 3.3yrs HK$200.00k Nessun dato
Mostra di più
Consiglio di amministrazione esperto: Il consiglio di amministrazione di 474 è composto da personale esperto e esperto (durata media dell'incarico 12.3 anni).
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}
